Lenalidomideas a Second-line Therapy Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory Multicentric Castleman's Disease：a Report of Two Cases and Literature Review

Lenalidomideas a Second-line Therapy Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory Multicentric Castleman's Disease：a Report of Two Cases and Literature Review

No standard therapy is recommended for elderly multicentric Castleman's disease (MCD) patients who failed to the first-line treatment or relapsed. Lenalidomide has been reported to be effective for relapsed/refractory MCD in foreign countries, but its effect on this disease has been rarely...

Full description

Bibliographic Details
Main Author: TANG Yangming, SHI Renzhou, LAN Mei, LI Xuejun, WEN Zonghua, LU Xiaochen
Format: Article
Language:zho
Published: Chinese General Practice Publishing House Co., Ltd 2022-01-01
Series:Zhongguo quanke yixue
Subjects:
|multicentric castleman's disease|aged|lenalidomide|recurrence|refractory diseases
Online Access:https://www.chinagp.net/fileup/1007-9572/PDF/1640773295382-617698484.pdf

Similar Items

Similar Items